Wockhardt gets USFDA nod for generic eye drops
New Delhi: Drug firm Wockhardt has received approval from the US health regulator for generic Olopatadine HCl eye drops used for the treatment of opthalmic allergies.
The company has received final approval from the United States Food and Drug Administration (USFDA) for Olopatadine HCl 0.1 per cent opthalmic solution, Wockhardt said in a BSE filing today.
The product is a generic version of Patanol, which is marketed in the US by Alcon, a subsidiary of pharma major Novartis, it added.
The product will be manufactured at a USFDA approved contract manufacturing organisation based in Montreal, Canada, Wockhardt said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd